Quantcast

Cancer Patients May Reduce Fast Growing Breast Cancer Recurrences: Findings Reported at 2010 San Antonio Breast Cancer Symposium

December 10, 2010

THE WOODLANDS, Texas, Dec. 10, 2010 /PRNewswire/ — Joyce O’Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research, and medical oncologist with Texas Oncology-Baylor Sammons Cancer Center, presented her study findings today at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

(Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO)

Her captivating study titled “First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Docetaxel with or without Capecitabine in High-Risk Early Breast Cancer” involved an innovative ten-year analysis focusing on high-risk early breast cancer. Her presentation provided an in-depth look at how faster growing breast cancers react to Xeloda® (capecitabine).

“Although the overall study results at the time of this analysis do not show that breast cancer recurrences are significantly decreased with the addition of Xeloda to standard chemotherapy, I think the study suggests that Xeloda may reduce recurrence of faster growing breast cancers,” said Dr. O’Shaughnessy. “Hopefully longer follow-up will confirm these findings.”

Dr. O’Shaughnessy is one of several internationally recognized investigators affiliated with US Oncology Research who participated in studies that are being presented, discussed and displayed Dec. 8-12 to a broad international audience of academic and private researchers and physicians from more than 90 countries. She and six other leading investigators participated in the following studies that have been or will be displayed as posters and poster discussions at the conference:


    --    Poster Discussions:
      o  7:00 am CST, Saturday, Dec. 11
        A Genomic Predictor of Survival Following
         Taxane-Anthracycline Chemotherapy for Breast
         Cancer
        Symmans WF, Hatzis C, Valero V, Booser DJ,
         Esserman L, Martin M, Vidaurre T, Holmes F,
         Souchon EA, Lluch A, Cotrina J, Gomez H,
         Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M,
         Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno
         NT, Hunt K, Yang W, Nazario A, DeMichele A,
         O'Shaughnessy J, Hortobagyi GN, Pusztai L.1

      o  5:30 pm CST, Thursday, Dec. 9
        Review of Capecitabine for the Treatment of
         Triple-Negative Early Breast Cancer
        Steger GG, Barrios C, O'Shaughnessy J, Martin M,
         Gnant M.

    --    Posters:
      o  7:00 am CST, Saturday, Dec. 11
        A Pilot Safety and Feasibility Study of
         Concurrent Capecitabine and External Beam
         Irradiation in the Adjuvant Treatment of High
         Risk Early Stage Breast Cancer
        Garwood DP, Spangler A, DeRose PM, Li HC,
         Osborne C, O'Shaughnessy J, Tripathy D.

      o  7:00 am CST, Sunday, Dec. 12
        Impact of the Number of Prior Chemotherapy
         Regimens on Overall Survival (OS) among
         Subjects with Locally Recurrent or Metastatic
         Breast Cancer Treated with Eribulin Mesylate:
         Results from the Phase III EMBRACE Study.
        Blum JL, Twelves CJ, Akerele C, Seegobin S,
         Wanders J, Cortes J.

      o  7:00 am CST, Sunday, Dec. 12
        Meta-analysis of patients with triple-negative
         disease from three randomized trials of
         bevacizumab (BV) and first-line chemotherapy
         as treatment for metastatic breast cancer
         (MBC).
        J O'Shaughnessy, G Romieu, V Dieras, M Byrtek,
         A-A Duenne, D Miles.

      o  7:00 am CST, Sunday, Dec. 12
        Survival Outcomes With Eribulin vs. Treatment of
         the Physician's Choice (TPC) in Heavily
         Pretreated Patients with Locally Recurrent or
         Metastatic Breast Cancer in North America,
         Western Europe, and Australia: Results of the
         Phase III EMBRACE Study
        C. Twelves1, D. Loesch2, J. Blum3, L. Vahdat4,
         K. Petrakova5, X. Durando6, S. Seegobin7, C.
         Dutcus8

      o  5:30 pm CST, Friday, Dec. 10
        Fibroblast Growth Factor Receptor 1
         Amplification and Overexpression in Breast
         Cancer Tissue Microarrays Using Chromogenic In
         Situ Hybridization and Immunohistochemistry
        Nuciforo P, Burzykowski T, Lambertini C, Gardner
         H, Liu WH, Lee B, Barzaghi-Rinaudo P,
         Rheinhardt J, Barrett C, Linnartz R, Dugan M,
         Hackl W, Eiermann W, Pienkowski T, Crown J,
         Robert N, Pawlicki M, Martin M, Finn R, Lindsay
         M-A, Slamon D, Press M.

      o  5:30 pm CST, Saturday, Dec. 11
        Ongoing Evaluation of Capecitabine-Based
         Therapy in Early Breast Cancer (EBC)
        Poole C, Barrios C, O'Shaughnessy J, Martin M,
         Mobus V.

Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, participated in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study that included more than 10,000 patients over a five-year period. Study results will be presented on Saturday, Dec. 11 as the following poster discussion and two poster displays:


    --    Poster Discussion:
      o  7:00 am CST, Saturday, Dec. 11
        Competing Causes of Mortality vs. Breast Cancer
         Mortality at 5-years among 9766 postmenopausal
         women with hormone receptor positive early
         breast cancer treated on the TEAM study of
         adjuvant hormonal therapy.
        Stephen E. Jones, Hein Putter, Annette
         Hasenburg, Cornelis J.H. van de Velde, Daniel
         Rea, Jean-Michel Vannetzel, Robert Paridaens,
         Christos Markopoulos, Yasuo Hozumi, Caroline
         Seynaeve.

    --    Posters:
      o  5:30 pm CST, Saturday, Dec. 11
        Discontinuation during tamoxifen in the
         sequential arm of the TEAM trial of adjuvant
         endocrine therapy in postmenopausal women with
         hormone-sensitive early breast cancer: the
         effect of IES results and subsequent therapy.
        Cornelis J. H. van de Velde, Elysee T. M. Hille,
         Daniel Rea, Caroline Seynaeve,  Annette
         Hasenburg, Jean-Michel Vannetzel,  Robert
         Paridaens, Christos Markopoulos, Yasuo Hozumi,
         Dirk G. Kieback,  Lina Asmar, Jan Smeets,
         Johan W. R. Nortier, Peyman Hadji, John M. S.
         Bartlett, Hein Putter,  Stephen E. Jones.

      o  5:30 pm CST, Saturday, Dec. 11
        Effects of exemestane or tamoxifen on bone
         health within the Tamoxifen Exemestane Adjuvant
         Multicentre (TEAM) trial: a meta-analysis
        P. Hadji, L. Asmar, J.G.H. van Nes, T. Menschik,
         A. Hasenburg, J. Kuck, H. Nortier, S.E. Jones,
         M. Ziller

Many clinical studies led by US Oncology Research Network physicians were also predominantly featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the American Society of Hematology (ASH) Annual Meeting and Exposition.

Those studies, along with more than 30 published manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow. For a complete list, please contact US Oncology at 281-863-1000.

About US Oncology

US Oncology, Inc. is the nation’s leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with 1,400 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit www.usoncology.com.

About US Oncology Research

US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary and the nation’s largest community-based cancer research network. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in 200 locations managing more than 200 active trials at any given time. The research network has enrolled nearly 47,000 patients in more than 1,100 trials since inception in 1992 and has contributed to the development of 43 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.

SOURCE US Oncology, Inc.


Source: newswire



comments powered by Disqus